Sonovia LTD

Their core work

Sonovia is an Israeli deep-tech SME that has developed a sonochemical process for permanently embedding antibacterial nanoparticles into textile fibers using ultrasound energy. Their one-step industrial coating method gives fabrics long-lasting antimicrobial properties without chemical binders or additional processing steps. The technology targets medical and healthcare textiles — hospital gowns, scrubs, bed linens — where infection control and resistant-bacteria prevention are critical requirements. They progressed from feasibility validation (SONO-textile, SME-1) to full commercial scale-up (Healthy Textile, SME-2), indicating a technology that passed EU scrutiny at both proof-of-concept and commercialization stages.

What they specialise in

How they've shifted over time

Sonovia's H2020 trajectory follows a textbook SME Instrument path: Phase 1 in 2017 (EUR 50,000, feasibility) proved the technical concept of one-step sonochemical coating; Phase 2 from 2019 to 2022 (EUR 2.35M, scale-up) translated that concept into a market-ready product and manufacturing process. No keyword data is available to detect finer thematic shifts, but the funding volume jump of nearly 47x between the two phases signals that the core technology did not change — what evolved was the commercialization readiness and production scale.

Sonovia is moving from R&D into commercialization — any future collaboration would likely be on industrial deployment, licensing, or market access rather than basic research.

How they like to work

Sonovia has coordinated both of its H2020 projects as a sole beneficiary, with no recorded consortium partners — a structure typical of SME Instrument grants where a single company drives the innovation. This means they are self-sufficient in executing their core technology and are not dependent on academic or industrial co-developers within funded projects. Partners engaging with Sonovia should expect to deal with a focused, product-oriented company rather than a collaborative research network.

Based on available H2020 data, Sonovia operated without formal consortium partners in either project, giving them zero recorded collaborative links across countries. Their network footprint in EU-funded research is minimal, though their Israeli base and participation under the EU-Israel association agreement marks them as an internationally-oriented company operating largely independently.

What sets them apart

Sonovia occupies a rare niche: an Israeli SME that has successfully navigated both phases of the EU SME Instrument with the same proprietary sonochemical technology, demonstrating sustained EU-level validation. Their ultrasound-based, one-step coating process is technically distinct from conventional chemical finishing methods used in the textile industry, offering potential partners a differentiated antimicrobial solution without wet chemistry. For consortia targeting infection-control, hospital procurement markets, or technical textile innovation, Sonovia brings a commercially validated, IP-backed technology rather than academic proof-of-concept work.

Highlights from their portfolio

• Healthy Textile
  The largest project by far at EUR 2.35M under SME Instrument Phase 2, representing a full commercial scale-up of sonochemical antibacterial textile coating and the primary vehicle for Sonovia's market entry.
• SONO-textile
  The Phase 1 feasibility study that initiated Sonovia's EU R&I journey, establishing the technical and commercial viability that unlocked the subsequent Phase 2 investment.